Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yijing Keli for Ovarian Aging
NCT06271928Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Oct 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Yijing Granules in ovarian aging, sponsored by Tongji Hospital. Primary endpoint: Recovery rate of ovarian function at 6 months. Started Oct 2021; status: recruiting.
02
Drugs
Yijing Granules
03
Conditions
ovarian aging
Beyond the preview
Go deeper on NCT06271928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06271928.